Abstract: Lactic acid bacteria have long been used to improve the safety of foods through fermentation. Some fermented products were also early used for their perceived health benefits, which lead to the development of probiotics as we now know them. Probiotics mainly belong to the genera Lactobacillus and Bifidobacterium. Most members of these genera are not considered pathogens or even opportunistic pathogens. Nevertheless, rare cases of Lactobacillus and Bifidobacterium infection have been reported, possibly even associated with the consumption of probiotic products. Such cases are extremely rare and the subjects always had severe underlying conditions most often affecting the immune system. There does not seem to be any risk for the general population. Safety assessments can be performed and many possible tests exist. It is, however, not certain these tests will prevent rare case of Lactobacillus infection in certain high-risk patients. The benefits of probiotic use should be weighed against the possible small risk. Such an evaluation will, in most cases, be favourable and should therefore not discourage consumption of probiotics.
Introduction
Foods have been fermented for thousands of years in all cultures. This spontaneous process was used to preserve foods and improve their safety. The understanding of the microbiology behind the fermentation made it possible to control it and improve quality, reproducibility, and safety through the use of defined starter cultures. Through the natural preservation in fermented foods, a number of species of lactic acid bacteria (LAB), such as Lactococcus lactis, Lactobacillus bulgaricus and Streptococcus thermophilus, have contributed to improving food safety, by providing preservation of perishable foods.
In addition to improving food safety, fermented foods, and in particular fermented dairy products, were also suggested to have beneficial health effects. This was, among others, promoted by Eli Metchnikoff (1907) at the beginning of last century. Over time, it was however, recognised that the traditional dairy starter cultures may not be suitable for eliciting health benefits in the gut. Therefore specific probiotic strains have been sought, which in most cases originate from the intestine (Havenaar et al., 1992) .
The different origin, intestine vs. milk, of probiotics and their specific properties, such as survival in the gastrointestinal tract, make the safety considerations for such strains different compared to starter cultures. Until recently the safety issue of probiotics received little attention. This is changing, as will be discussed. It is however not yet clear how this should be done. LAB used in the fermentation and probiotic industry are, in general, benign. It is relatively easy to show a microbe has potential pathogenic properties, by assessing the presence of known virulence factors both by phenotypic and genotypic methods (Isenberg, 2004) . However, it is much more difficult to show a microbe does not possess such characteristics. In addition to this, one has also to take into account the role of the host as a number of predisposing conditions appear to exist that are associated with an increased risk for infections; in particular reduced immune function (Salminen et al., 2004 , Boyle et al., 2006 . These are the challenges probiotic safety research is facing. A potential sequence to determine the safety of a new probiotic lactic acid bacterium strain is depicted in Figure 1 . 
Taxonomy
Safety assessment is a difficult but essential phase in the development of any new food. This is especially important when dealing with microorganisms, including probiotics, as in microbiology there is no zero risk. Pathogens can be found all along the bacterial phylogenetic tree, indicating the lack of common pathogenicity features for all of them and the need to clearly identify the pathogenicity traits associated with specific bacteria. In some cases, similar properties are found in clinical and non-clinical probiotic isolates (Ouwehand et al., 2004a,b) , indicating that not only the bacterial factors but also factors associated with the host may play a role in the pathogenicity. In this context, in addition to host factors the key target is to identify the possible risks associated with each probiotic strain, as different strains can possess different characteristics. It is clear then, that the first step in the safety assessment of a probiotic should be a proper identification of the strain. This would situate the strain in the appropriate taxonomical level allowing the preliminary establishment of the potential risks by using the previous knowledge about the corresponding taxonomical unit.
Moreover, a reliable probiotic product requires the correct identification of the species used and their announcement on the product label. Attention to such features is important, as it has been repeatedly shown that in about 50% of the probiotic products the identity of recovered microorganisms does not correspond to the information stated on the product label (Yeung et al., 2002; Fasoli et al., 2003; Temmerman et al., 2003; Theunissen et al., 2005) .
Traditionally, phenotypical methods, such as carbohydrate fermentation profiles, have been used for identification of probiotic bacteria. However, these methods, although easy and informative, do not always give reliable information. In recent years the rapid advance of molecular biology has lead to the development of numerous new methods, providing reliable techniques for proper identification of microorganisms. The availability of these methods makes the improper identification and labelling of probiotics unacceptable. Mislabelling may have serious safety implications. For example, mislabelling closely related species of lactobacilli maybe is not too worrying, but failure to properly identify or label the bacterial genus such as products labelling Lactobacillus acidophilus and containing Streptococcus sanguis (Yeung et al., 2002) or failure to list bacterial contents such as Enterococcus (Yeung et al., 2002) or Staphylococcus (Fasoli et al., 2003) are concerning from the point of view of safety of those products. These observations indicate the importance of rigorous quality control at every stage of the production and of each production batch. In addition, as part of the quality control, a viable number should be guaranteed at end of shelf life, not the number the viable count at production.
A proper identification of the probiotic strain is thus necessary to identify the specific safety risks associated with the microorganism and to avoid the inclusion of potential pathogenic microorganisms in commercial products.
Safety assessment
In vitro assessment of risk factors In order to assess the safety of a novel or existing strain in vitro, it has to be known what kind of properties could be considered risk properties of a strain. For generally non-pathogenic microbes as starter cultures and probiotics, this is not known and the best option is to search for properties that are known to be virulence or risk factors in 'true' pathogens. Such properties are e.g. platelet aggregation, haemolysis, resistance to complement-mediated killing, adhesion to extra cellular matrix proteins, antibiotic resistance, etc. (Fig. 2 ). These properties have been investigated for bifidobacteria (Ouwehand et al., 2004a) and lactobacilli (Baumgartner et al. 1998 ) and compared between probiotic strains, clinical blood isolates and faecal isolates.
Metabolic end products
In addition to intrinsic properties of microbes, also the metabolic activity may play a role. In particular the ability to form D-lactic acid, but also other substances, such as biogenic amines, have been suggested to be a potential risk factor. The risk for D-lactic acidosis appears to be mainly limited to children with short-bowel syndrome (SBS) (Bongaerts et al., 1997) . Human tissue contains the enzyme D-2-hydroxy acid dehydrogenase that also converts D-lactate to pyruvate and reduces the risk for acidosis. However, if absorption of D-lactate exceeds metabolism, e.g. during over growth of lactobacilli in SBS patients, acidosis may occur. On the other hand, a L-lactate producing probiotic (Lactobacillus GG) has been used in the treatment of D-lactic acidosis (Gavazzi et al., 2001) . The production of biogenic amines may happen in fermented dairy products that are ripened for longer periods of time; e.g. cheese and is therefore a minor concern for probiotics.
Antimicrobial resistance
The most important risk factor that can be assessed in vitro is transferable antibiotic resistance. Antibiotic resistance is common among microbes and dairy starters and probiotics are no exception to this. The reason for this is that most antibiotics target specific functions within the microbial cell and even broad-spectrum antibiotics will not affect all microbes, due to intrinsic resistance properties. For probiotics, the most notable example of this is the intrinsic resistance of Lactobacillus rhamnosus to vancomycin. Due to a different structure in the cell wall, L. rhamnosus strains are resistant to vancomycin. This resistance is, however, very different from the acquired resistance of certain strains of Enterococcus faecium (Tynkkynen et al., 1998) . Transferable antibiotic resistance, or in more broader terms the ability to acquire or pass on genetic material, is therefore undoubtedly the most relevant risk factor of consideration for probiotics and starter cultures. This has already been pointed out by the Scientific Committee for Animal Nutrition of the EU (Scientific committee on animal nutrition, 2002). This is also one of the main reasons of concern towards Enterococcus probiotics; their ability to transfer genetic material and their involvement in nosocomial infections (Franz et al., 1999) .
In vivo assessment of risk factors
Diverse experimental animal models have been extensively used for evaluating the effect of probiotics on their host. In many instances, health data generated from evaluating probiotics in animal models has given rise to similar outcomes in humans, and vice versa.
Although health benefits should always be confirmed in the host species targeted, the validity of extrapolation has generally been considered satisfactory, providing confidence in the safety assessment of probiotics intended for human use.
A number of studies have examined the effects of probiotics in experimentally-induced colitis in murine models by using transgenic animals or by use of chemicals, such as dextran sodium sulfate (DSS) or 2,4,6-trinitrobenzene sulfonic acid (TNBS). Despite disruption of the intestinal barrier in colitic animals, sideeffects due to increased probiotic bacteria translocation seem not to be apparent. In contrast, improvement of clinical condition by reducing inflammatory colitis of these animals has been a constant (Pavan et al., 2003; Pena et al., 2005) .
Germ-free mice are immune suppressed animals with an immature intestinal barrier and an underdeveloped immune system. The monoassociation between this gnotobiotic murine model and probiotics or/and pathogens has been assessed. Whilst pathogens induce a wide variety of side-effects and disease in these animal models, probiotics are reported to improve the host immunity without other adverse-effects (Ishibashi & Yamazaki, 2001) .
A retrospective review of probiotic endocarditis in clinical patients has recently been published, and the presence of Lactobacillus in their heart valves has been referred to as a 'marker of serious underlying illness and poor long-term prognosis'. However, only a few studies on bacterial endocarditis associated with probiotics in experimental animals have been reported, and increased susceptibility by an immune suppressed host may account for the pathogenesis . To study this, an endocarditis model in rabbits has been proposed (Asahara et al., 2003) . This model was, however designed to investigate the treatment of endocarditis and not the induction of it.
Genomic assessment of risk factors
With an increasing number of microbes being sequenced, the available genome can also be used for the detection of potential risk factors. Altermann et al. (2005) did so for the genome of L. acidophilus NCFM, where no transferable antibiotic resistance could be detected. Other probiotics strains are being sequenced and will allow a wider approach for these kinds of investigations.
The role of the host
In any infection, there are two parties involved; the microbe and the host. Above, we have considered the potential role of microbe. However, it is important to determine the role of the host in the process as well.
With the exception of enterococci, which may be involved in nosocomial infections, LAB are extremely rarely involved in infection. Infections rates for lactobacilli have been estimated at 0.1-0.4% (Gasser, 1994; Saxelin et al., 1996; Salminen et al., 2004) of all blood infections. For bifidobacteria these number appear to be at least a factor of 10 lower (Salminen et al., 2002) . What groups of patients may contract Lactobacillus infections? An investigation of patients with positive cases of lactobacillaemia indicated they were in general suffering from severe underlying diseases; malignancies and serious gastrointestinal disorders. Reduced immune function is the main common denominator in these patients. Such patients are prone to bacteraemia in general and not LAB in particular (Salminen et al., 2004) .
A search of the literature does not indicate positive cases of infection caused by traditional starter cultures. However, some suspected cases of infection caused by a probiotic strain do exist. Here, it is of extreme importance identification is performed correctly. But even when it is performed by state of the art molecular techniques, it may be difficult to confirm that probiotic and clinical isolate are the same strain. For example, pulsed field gel electrophoresis, one of the standard techniques for distinguishing between strains, actually compares only a small percentage of the total genome. This leaves the possibility open, although maybe not very likely, that two isolates are actually not identical (Ouwehand et al., 2004b) .
A number of cases of fungemia, caused by the probiotic yeast Saccharomyces cerevisiae (boulardii), have been reported (Lherm et al., 2002) . It is however not entirely clear whether all of these infections have been caused through the enteral route or through uncareful handling of the material and contamination of a central venous catheter.
One of the first reports on the possible involvement of a probiotic strain in endocarditis was from HamiltonMiller and co workers (Mackay et al., 1999) . After dental extraction the subject was found to be infected by a L. rhamnosus strain indistinguishable from the probiotic L. rhamnosus the patient used to consume. However, identification was based on phenotypic characteristics and pyrolysis mass spectrometry, which are maybe not sufficiently reliable for undisputable identification.
A liver abscess caused by a L. rhamnosus strain indistinguishable from Lactobacillus GG was described by Rautio et al. (1999) . This patient was suffering from diabetes. In a survey of blood culture isolates in Finland (see also below), 89 cases of Lactobacillus bacteraemia were identified. Of these, 11 were indistinguishable from Lactobacillus GG based on PFGE analysis with 4 different restriction enzymes (Salminen et al., 2002; 2004) . However, analysis of the phenotypic properties of these Lactobacillus GG-like isolates indicated they differed in one or more properties (Ouwehand et al., 2004b) . Furthermore, it is not clear whether these patients actually had consumed a Lactobacillus GG containing product. Two cases of Lactobacillus GG-like infections were reported by Land et al (2005) , in paediatric patients with each a combination of disorders. A further case of paediatric Lactobacillus GG-like bacteraemia was reported by de Groote et al. (2005) . Here, too, the patient had a severe underlying disorder, short bowel.
These rare cases of infection, possibly caused by probiotics, should not be overemphasised, but it should be borne in mind that in certain group of patients, there may be a small risk for infection caused by probiotics. This should not in any case discourage the use of probiotics. Specific strains of probiotics have very well established health benefits (Ouwehand et al., 2003) that far out weigh the small potential risk. Furthermore, data from Finland suggest that despite a substantial increase in probiotic consumption, there has not been any increase in Lactobacillus bacteraemia (Salminen et al., 2002) .
Although much safety testing can be suggested, as described above, it is not certain that it would prevent such rare cases of Lactobacillus infection as described here.
Post-marketing assessment
A company marketing a product, also probiotics, is ultimately responsible for its safety. Continuous quality control is an important aspect in assuring the safety and reliability of the product. In addition to this, post marketing assessment can complement the quality and safety assurance. In Finland a programme exists for assessing the cause of bacteraemia. In this programme, all blood culture isolates are identified, this way rare causes of bacteraemia are also identified including lactobacilli and bifidobacteria (Salminen et al., 2002) . From this study, it also becomes clear that despite a dramatic increase in consumption of probiotic products in Finland over the past ten years, there has been no increase in lactobacillaemia indicating the safety of probiotic products. A programme like this partic- 
Classification of safe organisms
A first attempt to make a classification on the safety of microbes, including LAB, was made by the German Union for the Chemical Industry. This list is actually intended for assessing the safety of workers in the biotechnology area, who may be exposed to far higher levels than consumers and also in other forms than food. Most controversial on the list has been the inclusion of L. rhamnosus as a class 2 organism, i.e. an organism that can cause disease. Although the species is marked that strains with a history of safe use exist. The importance of the list for the general population is a point of discussion (Berufsgenossenschaft der chemischen Industrie, 1998).
The International Dairy Federation and the European Food and Feed Cultures Association have composed a list of organisms with documented use in food (Mogensen et al., 2002a) . The list does not guarantee safety, but is an important indicator of safe use (Mogensen et al., 2002b) . The list is meant to be dynamic and will be modified over time. One of the discussion points is the use of species rather then strains on the list. For traditional dairy starter cultures this is not a concern. However, for probiotic strains of genera such as Enterococcus it would be important to distinguish strains with a history of apparent safe use in food and probiotics from those that e.g. cause nosocomial infections.
In the US, a manufacturer can apply for Generally Recognised As Safe (GRAS) status from the Food and Drug Administration. FDA GRAS approval is related to a specific application, e.g. L. bulgaricus and S. thermophilus have GRAS approval for yogurt production. In addition, there is self affirmed GRAS where the producer submits a file to the FDA, when the FDA does not object, it is assumed safe and can be marketed. A summary of GRAS approved microbes (not only probiotics) is given in Table 1 .
The possibility to create a system similar to the GRAS definition used in USA has been proposed to be used by the European Food Safety Agency (EFSA) aiming at the development of a QPS (Qualified Presumption of Safety) system for specific microorganisms or groups of microorganisms. The QPS approach would allow the establishment of specific safety assessment steps that should be fulfilled for each taxomomic unit (genus, species or strains depending on the microorganisms) suitable for QPS status. Thus, a given probiotic could have "QPS", "QPS with qualifications" or "Not suitable for QPS" status and only in the latter case the strain will have to go through a full risk assessment. This approach should facilitate the safety assessment by EFSA of certain microorganisms for which there are no special safety concerns, like lactobacilli or bifidobacteria, without wasting resources on thorough and repetitive investigations with these microorganisms.
Ironically the most clear and strict rules and regulations for probiotics in the EU are for animal applications, drawn up by the Scientific Committee on Animal Nutrition (SCAN) (Scientific Committee on Animal Nutrition, 2003) . These rules are strict and each new microbe intended to be added to a feed needs to acquire approval based on an extensive dossier. In particular, absence of transferable antibiotic resistance is one of the main approval criteria. A list of SCAN ap-proved microorganisms for veterinary use is given in Table 1 .
However, in order to facilitate approval, the committee proposed QPS, an approach now proposed to be by EFSA. In the case where the new probiotic is found to be a novel food, an extensive legislative procedure exists for the EU. Although the novel food legislation has been applied to selected foods, it has not been applied to probiotics.
Conclusions
Selected strains of probiotics have specific health benefits and fermented dairy products play an important role in nutrition. The microbes present in such products do not appear to pose any risk to the general population. There may exist a small group of patients, in particular those with severely compromised immune function that is more prone to infections, even by lactobacilli or bifidobacteria. This should not discourage the use of probiotics, not even in immune compromised subjects. However, one needs to be aware of the potential small risk in this group, which may nevertheless still be out weighed by the potential benefits.
